ArticleCurrent issues in molecular biology2025
Biomarkers of Endothelial Damage and Disease Severity in COVID-19 Patients.
Article in Current issues in molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SCUBE-1 as a Biomarker Predictor for the Home Follow-Up and Hospitalization of SARS-CoV-2 Patients.Journal of clinical medicine · 2026Article
- Immune effector cell-associated neurotoxicity syndrome: integrative mechanisms, predictive biomarkers, and translational pathways for prevention in CAR T-cell therapy.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The severe outbreak of SARS-CoV-2, the etiological agent of COVID-19, has precipitated the development of vaccines and antiviral therapeutics. However, it remains a significant public health concern. This study investigated the association between disease severity, biomarkers of coagulation, and endothelial damage, including P-selectin, thrombomodulin, PAI, von Willebrand antigen (VWF: Ag) and von Willebrand factor ristocetin cofactor (VWF: RCo). A cross-sectional, observational study was conducted in a cohort of 90 adult COVID-19 patients (≥18 years), categorized into three groups: ICU-hospitalized, non-ICU hospitalized, and asymptomatic non-hospitalized (outpatient). In these groups, biomarkers, including PAI-1, TM, and P-selectin, were assessed using enzyme-linked immunosorbent assay (ELISA), and immunological assays for VWF: Ag and VWF: RCo. Across all groups, we observed significantly elevated levels of P-selectin, VWF: Ag, and VWF: RCo. Elevated levels of PAI-1 and TM were observed in ICU patients compared to non-ICU and asymptomatic patients, indicating increased endothelial injury and activation. Furthermore, COVID-19 mutations significantly affect the P-selectin biomarker. This finding supports the hypothesis that P-selectin is a more reliable biomarker for assessing the severity of the disease than other endothelial damage and coagulation markers, especially in heterogeneous clinical presentations. Our study also highlights the requirement of comprehensive examination for its broader implications in viral strains, infection severity, and genetic variants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.